Tools and techniques for the discovery of therapeutic aptamers: recent advances

References

• Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249(4968):505–510. doi: 10.1126/science.2200121
   PubMed Web of Science ®Google Scholar
• Ellington AD, Szostak J. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990;346(6287):818–822. doi: 10.1038/346818a0
   PubMed Web of Science ®Google Scholar
• Yang G, Li Z, Mohammed I, et al. Identification of SARS-CoV-2-against aptamer with high neutralization activity by blocking the RBD domain of spike protein 1. Signal Transduct Target Ther. 2021;6(1):227. doi: 10.1038/s41392-021-00649-6
   PubMed Web of Science ®Google Scholar
• Cheng EL, Cardle II, Kacherovsky N, et al. Discovery of a transferrin receptor 1-binding aptamer and its application in cancer cell depletion for adoptive T-cell therapy manufacturing. J Am Chem Soc query. 2022;144(30):13851–13864. doi: 10.1021/jacs.2c05349
   PubMed Web of Science ®Google Scholar
• Gao T, Pei R. Isolation of DNA aptamer targeting PD-1 with an antitumor immunotherapy effect. ACS Appl Bio Mater. 2020;3(10):7080–7086. doi: 10.1021/acsabm.0c00919
   PubMedGoogle Scholar
• Patel DJ, Suri AK, Jiang F, et al. Structure, recognition and adaptive binding in RNA aptamer complexes. J Mol Biol. 1997;272(5):645–664. doi: 10.1006/jmbi.1997.1281
   PubMed Web of Science ®Google Scholar
• Jenison RD, Gill SC, Pardi A, et al. High-resolution molecular discrimination by RNA. Science. 1994;263(5152):1425–1429. doi: 10.1126/science.7510417
   PubMed Web of Science ®Google Scholar
• Mairal T, Ozalp VC, Lozano Sánchez P, et al. Aptamers: molecular tools for analytical applications. Anal Bioanal Chem. 2008;390(4):989–1007. doi: 10.1007/s00216-007-1346-4
   PubMed Web of Science ®Google Scholar
• Sefah K, Tang ZW, Shangguan DH, et al. Molecular recognition of acute myeloid leukemia using aptamers. Leukemia. 2009;23(2):235–244. doi: 10.1038/leu.2008.335
   PubMed Web of Science ®Google Scholar
• Bunka DH, Stockley PG. Aptamers come of age - at last. Nat Rev Microbiol. 2006;4(8):588–596. doi: 10.1038/nrmicro1458
   PubMed Web of Science ®Google Scholar
• Nakatsuka N, Yang KA, Abendroth JM, et al. Aptamer-field-effect transistors overcome Debye length limitations for small-molecule sensing. Science. 2018;362(6412):319–324. doi: 10.1126/science.aao6750
   PubMed Web of Science ®Google Scholar
• Lotz TS, Halbritter T, Kaiser C, et al. A light-responsive RNA aptamer for an azobenzene derivative. Nucleic Acids Res. 2019;47(4):2029–2040. doi: 10.1093/nar/gky1225
   PubMed Web of Science ®Google Scholar
• Arroyo-Currás N, Somerson J, Vieira PA, et al. Real-time measurement of small molecules directly in awake, ambulatory animals. Proc Natl Acad Sci U S A. 2017;114(4):645–650. doi: 10.1073/pnas.1613458114
   PubMed Web of Science ®Google Scholar
• Sefah K, Shangguan D, Xiong X, et al. Development of DNA aptamers using cell-SELEX. Nat Protoc. 2010;5(6):1169–1185. doi: 10.1038/nprot.2010.66
   PubMed Web of Science ®Google Scholar
• Wu X, Liu H, Han D, et al. Elucidation and structural modeling of CD71 as a molecular target for cell-specific aptamer binding. J Am Chem Soc. 2019;141(27):10760–10769. doi: 10.1021/jacs.9b03720
   PubMed Web of Science ®Google Scholar
• Wu X, Zhao Z, Bai H, et al. DNA aptamer selected against pancreatic ductal adenocarcinoma for in vivo imaging and clinical tissue recognition. Theranostics. 2015;5(9):985–994. doi: 10.7150/thno.11938
   PubMed Web of Science ®Google Scholar
• Li L, Wan J, Wen X, et al. Identification of a new DNA aptamer by tissue-SELEX for cancer recognition and imaging. Anal Chem. 2021;93(19):7369–7377. doi: 10.1021/acs.analchem.1c01445
   PubMed Web of Science ®Google Scholar
• Pu Y, Xiang J, Zhang X, et al. CD36 as a molecular target of functional DNA aptamer NAFLD01 selected against NAFLD cells. Anal Chem. 2021;93(8):3951–3958. doi: 10.1021/acs.analchem.0c04866
   PubMed Web of Science ®Google Scholar
• Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2017;16(3):181–202. doi: 10.1038/nrd.2016.199
   PubMed Web of Science ®Google Scholar
• Berzal-Herranz A, Romero-López C. Two examples of RNA aptamers with antiviral activity. Are aptamers the wished antiviral drugs? Pharmaceuticals (Basel). 2020;13(8):157. doi: 10.3390/ph13080157
   PubMedGoogle Scholar
• Sun M, Liu S, Wei X, et al. Aptamer blocking strategy inhibits SARS-CoV-2 virus infection. Angew Chem Int Ed. 2021;60(18):10266–10272. doi: 10.1002/anie.202100225
   PubMed Web of Science ®Google Scholar
• Wang L, Liang H, Sun J, et al. Bispecific aptamer induced artificial protein-pairing: a strategy for selective inhibition of receptor function. J Am Chem Soc. 2019;141(32):12673–12681. doi: 10.1021/jacs.9b05123
   PubMed Web of Science ®Google Scholar
• Jin B, Guo Z, Chen Z, et al. Aptamers in cancer therapy: problems and new breakthroughs. J Mater Chem B. 2023;11(8):1609–1627. doi: 10.1039/D2TB02579E
   PubMed Web of Science ®Google Scholar
• He J, Duan Q, Ran C, et al. Recent progress of aptamer‒drug conjugates in cancer therapy. Acta Pharm Sin B. 2023;13(4):1358–1370. doi: 10.1016/j.apsb.2023.01.017
   PubMed Web of Science ®Google Scholar
• Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5(2):123–132. doi: 10.1038/nrd1955
   PubMed Web of Science ®Google Scholar
• Razlansari M, Jafarinejad S, Rahdar A, et al. Development and classification of RNA aptamers for therapeutic purposes: an updated review with emphasis on cancer. Mol Cell Biochem. 2023;478:1573–1598.
   PubMed Web of Science ®Google Scholar
• Darmostuk M, Rimpelova S, Gbelcova H, et al. Current approaches in SELEX: an update to aptamer selection technology. Biotechnol Adv. 2015;33(6 Pt 2):1141–1161. doi: 10.1016/j.biotechadv.2015.02.008
   PubMed Web of Science ®Google Scholar
• Guo KT, Ziemer G, Paul A, et al. CELL-SELEX: novel perspectives of aptamer-based therapeutics. Int J Mol Sci. 2008;9(4):668–678. doi: 10.3390/ijms9040668
   PubMed Web of Science ®Google Scholar
• Klett-Mingo JI, Pinto-Díez C, Cambronero-Plaza J, et al. Potential therapeutic use of aptamers against HAT1 in lung cancer. Cancers (Basel). 2022;15(1):227. doi: 10.3390/cancers15010227
   PubMed Web of Science ®Google Scholar
• Bala J, Bhaskar A, Varshney A, et al. In vitro selected RNA aptamer recognizing glutathione induces ROS mediated apoptosis in the human breast cancer cell line MCF 7. RNA Biol. 2011;8(1):101–111. doi: 10.4161/rna.8.1.14116
   PubMed Web of Science ®Google Scholar
• Fortenberry Y, Abdulameer Z, Barak M, et al. Antithrombin-specific RNA aptamers as a potential therapy to restore hemostatic balance in hemophilia patients. Blood. 2022;140(Supplement 1):11275–11275. doi: 10.1182/blood-2022-166896
   Google Scholar
• Tsukakoshi K, Abe K, Sode K, et al. Selection of DNA aptamers that recognize α-synuclein oligomers using a competitive screening method. Anal Chem. 2012;84(13):5542–5547. doi: 10.1021/ac300330g
   PubMed Web of Science ®Google Scholar
• Rahimi F, Bitan G. Selection of aptamers for amyloid beta-protein, the causative agent of Alzheimer’s disease. J Vis Exp. 2010;39:1955–1955. doi: 10.3791/1955
   PubMedGoogle Scholar
• Jang KJ, Lee NR, Yeo WS, et al. Isolation of inhibitory RNA aptamers against severe acute respiratory syndrome (SARS) coronavirus NTPase/Helicase. Biochem Biophys Res Commun. 2008;366(3):738–744. doi: 10.1016/j.bbrc.2007.12.020
   PubMed Web of Science ®Google Scholar
• Lai YT, DeStefano JJ. DNA aptamers to human immunodeficiency virus reverse transcriptase selected by a primer-free SELEX method: characterization and comparison with other aptamers. Nucleic Acid Ther. 2012;22(3):162–176. doi: 10.1089/nat.2011.0327
   PubMed Web of Science ®Google Scholar
• Feng H, Beck J, Nassal M, et al. A SELEX-screened aptamer of human hepatitis B virus RNA encapsidation signal suppresses viral replication. PLoS One. 2011;6(11):e27862. doi: 10.1371/journal.pone.0027862
   PubMed Web of Science ®Google Scholar
• Joshi P, Prasad VR. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J Virol. 2002;76(13):6545–6557. doi: 10.1128/JVI.76.13.6545-6557.2002
   PubMed Web of Science ®Google Scholar
• Lai YT, DeStefano JJ. A primer-free method that selects high-affinity single-stranded DNA aptamers using thermostable RNA ligase. Anal Biochem. 2011;414(2):246–253. doi: 10.1016/j.ab.2011.03.018
   PubMed Web of Science ®Google Scholar
• Graham JC, Zarbl H, Deutsch E. Use of cell-SELEX to generate DNA aptamers as molecular probes of HPV-associated cervical cancer cells. PLoS One. 2012;7(4):e36103. doi: 10.1371/journal.pone.0036103
   PubMed Web of Science ®Google Scholar
• Maimaitiyiming Y, Yang C, Wang Y, et al. Selection and characterization of novel DNA aptamer against colorectal carcinoma caco-2 cells. Biotechnol Appl Biochem. 2019;66(3):412–418. doi: 10.1002/bab.1737
   PubMed Web of Science ®Google Scholar
• Rong Y, Chen H, Zhou XF, et al. Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers. Oncotarget. 2016;7(7):8282–8294. doi: 10.18632/oncotarget.6988
   PubMedGoogle Scholar
• Shi H, Cui W, He X, et al. Whole cell-SELEX aptamers for highly specific fluorescence molecular imaging of carcinomas in vivo. PLoS One. 2013;8(8):e70476. doi: 10.1371/journal.pone.0070476
   PubMed Web of Science ®Google Scholar
• Wang Y, Luo Y, Bing T, et al. DNA aptamer evolved by cell-SELEX for recognition of prostate cancer. PLoS One. 2014;9(6):e100243. doi: 10.1371/journal.pone.0100243
   PubMed Web of Science ®Google Scholar
• Wu Q, Wang Y, Wang H, et al. DNA aptamers from whole-cell SELEX as new diagnostic agents against glioblastoma multiforme cells. Analyst. 2018;143(10):2267–2275. doi: 10.1039/C8AN00271A
   PubMed Web of Science ®Google Scholar
• Zhang K, Sefah K, Tang L, et al. A novel aptamer developed for breast cancer cell internalization. ChemMedchem. 2012;7(1):79–84. doi: 10.1002/cmdc.201100457
   PubMed Web of Science ®Google Scholar
• He J, Wang J, Zhang N, et al. In vitro selection of DNA aptamers recognizing drug-resistant ovarian cancer by cell-SELEX. Talanta. 2019;194:437–445. doi: 10.1016/j.talanta.2018.10.028
   PubMed Web of Science ®Google Scholar
• Esposito CL, Passaro D, Longobardo I, et al. A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS One. 2011;6(9):e24071. doi: 10.1371/journal.pone.0024071
   PubMed Web of Science ®Google Scholar
• Tang Z, Parekh P, Turner P, et al. Generating aptamers for recognition of virus-infected cells. Clin Chem. 2009;55(4):813–822. doi: 10.1373/clinchem.2008.113514
   PubMed Web of Science ®Google Scholar
• Liang HR, Liu Q, Zheng XX, et al. Aptamers targeting rabies virus-infected cells inhibit viral replication both in vitro and in vivo. Virus Res. 2013;173(2):398–403. doi: 10.1016/j.virusres.2012.12.017
   PubMed Web of Science ®Google Scholar
• Haghighi M, Khanahmad H, Palizban A. Selection and characterization of single-stranded DNA aptamers binding human B-cell surface protein CD20 by cell-SELEX. Molecules. 2018;23(4):715. doi: 10.3390/molecules23040715
   PubMed Web of Science ®Google Scholar
• Moghadam M, Sankian M, Abnous K, et al. Cell-SELEX-based selection and characterization of a G-quadruplex DNA aptamer against mouse dendritic cells. Int Immunopharmacol. 2016;36:324–332. doi: 10.1016/j.intimp.2016.04.042
   PubMed Web of Science ®Google Scholar
• Gao T, Mao Z, Li W, et al. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect. J Mater Chem B. 2021;9(3):746–756. doi: 10.1039/D0TB01668C
   PubMed Web of Science ®Google Scholar
• Kim Y, Liu C, Tan W. Aptamers generated by cell SELEX for biomarker discovery. Biomarker Med. 2009;3(2):193–202. doi: 10.2217/bmm.09.5
   PubMed Web of Science ®Google Scholar
• Bing T, Zhang N, Shangguan D. Cell-SELEX, an effective way to the discovery of biomarkers and unexpected molecular events. Adv Biosyst. 2019;3(12):e1900193. doi: 10.1002/adbi.201900193
   PubMed Web of Science ®Google Scholar
• McNamara JO, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRnas with aptamer-siRNA chimeras. Nat Biotechnol. 2006;24(8):1005–1015. doi: 10.1038/nbt1223
   PubMed Web of Science ®Google Scholar
• Huang YZ, Hernandez FJ, Gu B, et al. RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB. Mol Pharmacol. 2012;82(4):623–635. doi: 10.1124/mol.112.078220
   PubMed Web of Science ®Google Scholar
• Thiel KW, Hernandez LI, Dassie JP, et al. Delivery of chemo-sensitizing siRnas to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res. 2012;40(13):6319–6337. doi: 10.1093/nar/gks294
   PubMed Web of Science ®Google Scholar
• Thiel WH, Thiel KW, Flenker KS, et al. Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRnas to target cells. Methods Mol Biol. 2015;1218:187–199.
   PubMedGoogle Scholar
• Ranches G, Lukasser M, Schramek H, et al. In vitro selection of cell-internalizing DNA aptamers in a model system of inflammatory kidney disease. Mol Ther Nucleic Acids. 2017;8:198–210. doi: 10.1016/j.omtn.2017.06.018
   PubMedGoogle Scholar
• Chen K, Cai J, Wang S, et al. Aptamer inhibits tumor growth by leveraging cellular proteasomal degradation system to degrade c-met in mice. Angew Chem Int Ed. 2023;62(2):e202208451. doi: 10.1002/anie.202208451
   PubMed Web of Science ®Google Scholar
• Haisler WL, Timm DM, Gage JA, et al. Three-dimensional cell culturing by magnetic levitation. Nat Protoc. 2013;8(10):1940–1949. doi: 10.1038/nprot.2013.125
   PubMed Web of Science ®Google Scholar
• Zümrüt HE, Batool S, Van N, et al. Structural optimization of an aptamer generated from ligand-guided selection (LIGS) resulted in high affinity variant toward mIgm expressed on Burkitt’s lymphoma cell lines. Biochim Biophys Acta Gen Subj. 2017;1861(7):1825–1832. doi: 10.1016/j.bbagen.2017.03.020
   PubMed Web of Science ®Google Scholar
• Chen L, He W, Jiang H, et al. In vivo SELEX of bone targeting aptamer in prostate cancer bone metastasis model. Int J Nanomedicine. 2019;14:149–159. doi: 10.2147/IJN.S188003
   PubMed Web of Science ®Google Scholar
• Cheng C, Chen YH, Lennox KA, et al. In vivo SELEX for identification of brain-penetrating aptamers. Mol Ther Nucleic Acids. 2013;2(1):e67. doi: 10.1038/mtna.2012.59
   PubMedGoogle Scholar
• Mendonsa SD, Bowser MT. In vitro selection of aptamers with affinity for neuropeptide Y using capillary electrophoresis. J Am Chem Soc. 2005;127(26):9382–9383. doi: 10.1021/ja052406n
   PubMed Web of Science ®Google Scholar
• Dong L, Tan Q, Ye W, et al. Screening and identifying a novel ssDNA aptamer against alpha-fetoprotein using CE-SELEX. Sci Rep. 2015;5(1):15552. doi: 10.1038/srep15552
   PubMedGoogle Scholar
• Lai HC, Wang CH, Liou TM, et al. Influenza a virus-specific aptamers screened by using an integrated microfluidic system. Lab Chip. 2014;14(12):2002–2013. doi: 10.1039/C4LC00187G
   PubMed Web of Science ®Google Scholar
• Stoltenburg R, Reinemann C, Strehlitz B. FluMag-SELEX as an advantageous method for DNA aptamer selection. Anal Bioanal Chem. 2005;383(1):83–91. doi: 10.1007/s00216-005-3388-9
   PubMed Web of Science ®Google Scholar
• Komarova N, Andrianova M, Glukhov S, et al. Selection, characterization, and application of ssDNA aptamer against Furaneol. Molecules. 2018;23(12):3159. doi: 10.3390/molecules23123159
   PubMed Web of Science ®Google Scholar
• Paniel N, Istamboulié G, Triki A, et al. Selection of DNA aptamers against penicillin G using capture-SELEX for the development of an impedimetric sensor. Talanta. 2017;162:232–240. doi: 10.1016/j.talanta.2016.09.058
   PubMed Web of Science ®Google Scholar
• Stoltenburg R, Nikolaus N, Strehlitz B. Capture-SELEX: selection of DNA aptamers for aminoglycoside antibiotics. J Anal Methods Chem. 2012;2012:415697. doi: 10.1155/2012/415697
   PubMed Web of Science ®Google Scholar
• Leblebici P, Leirs K, Spasic D, et al. Encoded particle microfluidic platform for rapid multiplexed screening and characterization of aptamers against influenza a nucleoprotein. Anal Chim Acta. 2019;1053:70–80. doi: 10.1016/j.aca.2018.11.055
   PubMed Web of Science ®Google Scholar
• Hung LY, Fu CY, Wang CH, et al. Microfluidic platforms for rapid screening of cancer affinity reagents by using tissue samples. Biomicrofluidics. 2018;12(5):054108. doi: 10.1063/1.5050451
   PubMed Web of Science ®Google Scholar
• Sinha A, Gopinathan P, Chung YD, et al. An integrated microfluidic platform to perform uninterrupted SELEX cycles to screen affinity reagents specific to cardiovascular biomarkers. Biosens Bioelectron. 2018;122:104–112. doi: 10.1016/j.bios.2018.09.040
   PubMed Web of Science ®Google Scholar
• Nitsche A, Kurth A, Dunkhorst A, et al. One-step selection of vaccinia virus-binding DNA aptamers by MonoLEX. BMC Biotechnol. 2007;7(1):48. doi: 10.1186/1472-6750-7-48
   PubMedGoogle Scholar
• Yue Y, Zhang D, Tian K, et al. Screening and evaluation of thiamethoxam aptamer based on pressurized GO-SELEX and its sensor application. Biosens (Basel). 2023;13(2):155. doi: 10.3390/bios13020155
   PubMedGoogle Scholar
• Kwon J, Narayan C, Kim C, et al. Development of a subtype-specific diagnostic system for influenza virus H3N2 using a novel virus-based Systematic evolution of ligands by exponential enrichment (viro-SELEX). J Biomed Nanotechnol. 2019;15(7):1609–1621. doi: 10.1166/jbn.2019.2789
   PubMed Web of Science ®Google Scholar
• Narayan C, Kwon J, Kim C, et al. Virus-based SELEX (viro-SELEX) allows development of aptamers targeting knotty proteins. Analyst. 2020;145(4):1473–1482. doi: 10.1039/C9AN01943J
   PubMed Web of Science ®Google Scholar
• Guo S, Xu Z, Lin L, et al. Using CIVT-SELEX to select aptamers as genetic parts to regulate gene circuits in a cell-free system. Int J Mol Sci. 2023;24(3):2833. doi: 10.3390/ijms24032833
   PubMed Web of Science ®Google Scholar
• Dupont DM, Larsen N, Jensen JK, et al. Characterisation of aptamer-target interactions by branched selection and high-throughput sequencing of SELEX pools. Nucleic Acids Res. 2015;43(21):e139. doi: 10.1093/nar/gkv700
   PubMed Web of Science ®Google Scholar
• Eaton RM, Shallcross JA, Mael LE, et al. Selection of DNA aptamers for ovarian cancer biomarker HE4 using CE-SELEX and high-throughput sequencing. Anal Bioanal Chem. 2015;407(23):6965–6973. doi: 10.1007/s00216-015-8665-7
   PubMed Web of Science ®Google Scholar
• Beier R, Pahlke C, Quenzel P, et al. Selection of a DNA aptamer against norovirus capsid protein VP1. FEMS Microbiol Lett. 2014;351(2):162–169. doi: 10.1111/1574-6968.12366
   PubMed Web of Science ®Google Scholar
• Setlem K, Mondal B, Ramlal S, et al. Immuno affinity SELEX for simple, rapid, and cost-effective aptamer enrichment and identification against aflatoxin B1. Front Microbiol. 2016;7:1909. doi: 10.3389/fmicb.2016.01909
   PubMed Web of Science ®Google Scholar
• Liu H, Zhou Y, Xu Q, et al. Selection of DNA aptamers for subcellular localization of RBSDV P10 protein in the midgut of small brown planthoppers by emulsion PCR-based SELEX. Viruses. 2020;12(11):1239. doi: 10.3390/v12111239
   PubMed Web of Science ®Google Scholar
• Matsunaga KI, Kimoto M, Lim VW, et al. High-affinity five/six-letter DNA aptamers with superior specificity enabling the detection of dengue NS1 protein variants beyond the serotype identification. Nucleic Acids Res. 2021;49(20):11407–11424. doi: 10.1093/nar/gkab515
   PubMed Web of Science ®Google Scholar
• Tanaka K, Okuda T, Kasahara Y, et al. Base-modified aptamers obtained by cell-internalization SELEX facilitate cellular uptake of an antisense oligonucleotide. Mol Ther Nucleic Acids. 2021;23:440–449. doi: 10.1016/j.omtn.2020.11.016
   PubMedGoogle Scholar
• Vaught JD, Bock C, Carter J, et al. Expanding the chemistry of DNA for in vitro selection. J Am Chem Soc. 2010;132(12):4141–4151. doi: 10.1021/ja908035g
   PubMed Web of Science ®Google Scholar
• Moore MD, Bunka DHJ, Forzan M, et al. Generation of neutralizing aptamers against herpes simplex virus type 2: potential components of multivalent microbicides. J Gen Virol. 2011;92(Pt 7):1493–1499. doi: 10.1099/vir.0.030601-0
   PubMedGoogle Scholar
• Han SR, Lee SW. Inhibition of Japanese encephalitis virus (JEV) replication by specific RNA aptamer against JEV methyltransferase. Biochem Biophys Res Commun. 2017;483(1):687–693. doi: 10.1016/j.bbrc.2016.12.081
   PubMed Web of Science ®Google Scholar
• Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003;31(13):3406–3415. doi: 10.1093/nar/gkg595
   PubMed Web of Science ®Google Scholar
• Akitomi J, Kato S, Yoshida Y, et al. ValFold: program for the aptamer truncation process. Bioinformation. 2011;7(1):38–40. doi: 10.6026/97320630007038
   PubMedGoogle Scholar
• Iwano N, Adachi T, Aoki K, et al. Generative aptamer discovery using RaptGen. Nat Compu Sci. 2022;2(6):378–386. doi: 10.1038/s43588-022-00249-6
   Google Scholar
• Jalali T, Salehi-Vaziri M, Pouriayevali MH, et al. Aptamer based diagnosis of crimean-congo hemorrhagic fever from clinical specimens. Sci Rep. 2021;11(1):12639. doi: 10.1038/s41598-021-91826-8
   PubMed Web of Science ®Google Scholar
• Puton T, Kozlowski LP, Rother KM, et al. CompaRNA: a server for continuous benchmarking of automated methods for RNA secondary structure prediction. Nucleic Acids Res. 2013;41(7):4307–4323. doi: 10.1093/nar/gkt101
   PubMed Web of Science ®Google Scholar
• Sükösd Z, Knudsen B, Vaerum M, et al. Multithreaded comparative RNA secondary structure prediction using stochastic context-free grammars. BMC Bioinf. 2011;12(1):103. doi: 10.1186/1471-2105-12-103
   PubMedGoogle Scholar
• Bernhart SH, Hofacker IL, Will S, et al. Rnaalifold: improved consensus structure prediction for RNA alignments. BMC Bioinf. 2008;9(1):474. doi: 10.1186/1471-2105-9-474
   PubMedGoogle Scholar
• Kiessling LL, Lamann AC. Multivalency of biological systems. In: Schneider MP, editor. Chemical probes in biology. Vol. 129. Springer Netherlands; 2003. p. 345–357.
   Google Scholar
• Wang Z, Yang X, Lee NZ, et al. Multivalent aptamer approach: designs, strategies, and applications. Micromachines (Basel). 2022;13(3):436. doi: 10.3390/mi13030436
   PubMed Web of Science ®Google Scholar
• Lin M, Zhang J, Wan H, et al. Rationally designed multivalent aptamers targeting cell surface for biomedical applications. ACS Appl Mater Interfaces. 2021;13(8):9369–9389. doi: 10.1021/acsami.0c15644
   PubMed Web of Science ®Google Scholar
• McNamara JO, Kolonias D, Pastor F, et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest. 2008;118(1):376–386. doi: 10.1172/JCI33365
   PubMed Web of Science ®Google Scholar
• Li X, Yang Y, Zhao H, et al. Enhanced in vivo blood-brain barrier penetration by circular tau-transferrin receptor bifunctional aptamer for tauopathy therapy. J Am Chem Soc. 2020;142(8):3862–3872. doi: 10.1021/jacs.9b11490
   PubMed Web of Science ®Google Scholar
• Ai L, Peng T, Li Y, et al. A dual-targeting circular aptamer strategy enables the recognition of different leukemia cells with enhanced binding ability. Angew Chem Int Ed. 2022;61(33):e202109500. doi: 10.1002/anie.202109500
   PubMed Web of Science ®Google Scholar
• Yang Y, Sun X, Xu J, et al. Circular bispecific aptamer-mediated artificial intercellular recognition for targeted T cell immunotherapy. ACS Nano. 2020;14(8):9562–9571. doi: 10.1021/acsnano.9b09884
   PubMed Web of Science ®Google Scholar
• Sun Y, Mo L, Hu X, et al. Bispecific aptamer-based recognition-then-conjugation strategy for PD1/PDL1 axis blockade and enhanced immunotherapy. ACS Nano. 2022;16(12):21129–21138. doi: 10.1021/acsnano.2c09093
   PubMed Web of Science ®Google Scholar
• Miao Y, Gao Q, Mao M, et al. Bispecific aptamer chimeras enable targeted protein degradation on cell membranes. Angew Chem Int Ed. 2021;60(20):11267–11271. doi: 10.1002/anie.202102170
   PubMed Web of Science ®Google Scholar
• Topalian SL. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr Opin Immunol. 1994;6(5):741–745. doi: 10.1016/0952-7915(94)90078-7
   PubMed Web of Science ®Google Scholar
• Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005;54(8):721–728. doi: 10.1007/s00262-004-0653-2
   PubMed Web of Science ®Google Scholar
• Kampen KR. Membrane proteins: the key players of a cancer cell. J Membr Biol. 2011;242(2):69–74. doi: 10.1007/s00232-011-9381-7
   PubMed Web of Science ®Google Scholar
• Yin H, Flynn AD. Drugging membrane protein interactions. Annu Rev Biomed Eng. 2016;18(1):51–76. doi: 10.1146/annurev-bioeng-092115-025322
   PubMedGoogle Scholar
• Zhou F, Wang P, Peng Y, et al. Molecular engineering-based aptamer-drug conjugates with accurate tunability of drug ratios for drug combination targeted cancer therapy. Angew Chem Int Ed. 2019;58(34):11661–11665. doi: 10.1002/anie.201903807
   PubMed Web of Science ®Google Scholar
• Kuai H, Zhao Z, Mo L, et al. Circular bivalent aptamers enable in vivo stability and recognition. J Am Chem Soc. 2017;139(27):9128–9131. doi: 10.1021/jacs.7b04547
   PubMed Web of Science ®Google Scholar
• Sun M, Wu Z, Zhang J, et al. Spherical neutralizing aptamer suppresses SARS-CoV-2 omicron escape. Nano Today. 2022;44:101499. doi: 10.1016/j.nantod.2022.101499
   PubMed Web of Science ®Google Scholar
• Wang Z, Xie S, Wu L, et al. Aptamer-functionalized nanodevices for dynamic manipulation of membrane receptor signaling in living cells. Nano Lett. 2022;22(19):7853–7859. doi: 10.1021/acs.nanolett.2c02522
   PubMedGoogle Scholar
• Chen S, Li J, Liang H, et al. Light-induced activation of c-Met signalling by photocontrolled DNA assembly. Chemistry A European J. 2018;24(60):15988–15992. doi: 10.1002/chem.201803868
   PubMed Web of Science ®Google Scholar
• Fan S, Ma YX, Wang JA, et al. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3’ kinase. Oncogene. 2000;19(18):2212–2223. doi: 10.1038/sj.onc.1203566
   PubMed Web of Science ®Google Scholar
• Derksen PW, de Gorter DJ, Meijer HP, et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia. 2003;17(4):764–774. doi: 10.1038/sj.leu.2402875
   PubMed Web of Science ®Google Scholar
• Xiao GH, Jeffers M, Bellacosa A, et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A. 2001;98(1):247–252. doi: 10.1073/pnas.98.1.247
   PubMed Web of Science ®Google Scholar
• Ueki R, Atsuta S, Ueki A, et al. Nongenetic reprogramming of the ligand specificity of growth factor receptors by bispecific DNA aptamers. J Am Chem Soc. 2017;139(19):6554–6557. doi: 10.1021/jacs.7b02411
   PubMed Web of Science ®Google Scholar
• Chen S, Xu Z, Yang W, et al. Logic-gate-actuated DNA-controlled receptor assembly for the programmable modulation of cellular signal transduction. Angew Chem Int Ed. 2019;58(50):18186–18190. doi: 10.1002/anie.201908971
   PubMed Web of Science ®Google Scholar
• Chen S, Xu Z, Li S, et al. Systematic interrogation of cellular signaling in live cells using a membrane-anchored DNA multitasking processor. Angew Chem Int Ed. 2022;61(11):e202113795. doi: 10.1002/anie.202113795
   PubMed Web of Science ®Google Scholar
• Liu S, Li S, Lin J, et al. Aptamer-induced-dimerization strategy attenuates AβO toxicity through modulating the trophic activity of PrP(C) signaling. J Am Chem Soc. 2022;144(21):9264–9270. doi: 10.1021/jacs.2c00287
   PubMed Web of Science ®Google Scholar
• Zhou F, Wang P, Chen J, et al. A photochemically covalent lock stabilizes aptamer conformation and strengthens its performance for biomedicine. Nucleic Acids Res. 2022;50(16):9039–9050. doi: 10.1093/nar/gkac703
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang D, Chen H, et al. A pH-responsive covalent nanoscale device enhancing temporal and force stability for specific tumor imaging. Nano Lett. 2022;22(23):9441–9449. doi: 10.1021/acs.nanolett.2c03487
   PubMedGoogle Scholar
• Yang Y, Xu J, Sun Y, et al. Aptamer-based logic computing reaction on living cells to enable non-antibody immune checkpoint blockade therapy. J Am Chem Soc. 2021;143(22):8391–8401. doi: 10.1021/jacs.1c02016
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang J, Huang Z, et al. Robust covalent aptamer strategy enables sensitive detection and enhanced inhibition of SARS-CoV-2 proteins. ACS Cent Sci. 2023;9(1):72–83. doi: 10.1021/acscentsci.2c01263
   PubMed Web of Science ®Google Scholar
• Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. BioEssays. 2000;22(5):442–451. doi: 10.1002/(SICI)1521-1878(200005)22:5<442:AID-BIES6>3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Zhou QQ, Xiao HT, Yang F, et al. Advancing targeted protein degradation for metabolic diseases therapy. Pharmacol Res. 2023;188:106627. doi: 10.1016/j.phrs.2022.106627
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhao J, Zhong K, et al. Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target Ther. 2022;7(1):113. doi: 10.1038/s41392-022-00966-4
   PubMed Web of Science ®Google Scholar
• Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181–200. doi: 10.1038/s41573-021-00371-6
   PubMed Web of Science ®Google Scholar
• Zou Y, Ma D, Wang Y. The PROTAC technology in drug development. Cell Biochem Funct. 2019;37(1):21–30. doi: 10.1002/cbf.3369
   PubMed Web of Science ®Google Scholar
• He S, Gao F, Ma J, et al. Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer. Angew Chem Int Ed. 2021;60(43):23299–23305. doi: 10.1002/anie.202107347
   PubMed Web of Science ®Google Scholar
• Zhang L, Li L, Wang X, et al. Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin. Mol Ther Nucleic Acids. 2022;30:66–79. doi: 10.1016/j.omtn.2022.09.008
   PubMedGoogle Scholar
• Banik SM, Pedram K, Wisnovsky S, et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature. 2020;584(7820):291–297. doi: 10.1038/s41586-020-2545-9
   PubMed Web of Science ®Google Scholar
• Zhang H, Han Y, Yang Y, et al. Covalently engineered nanobody chimeras for targeted membrane protein degradation. J Am Chem Soc. 2021;143(40):16377–16382. doi: 10.1021/jacs.1c08521
   PubMed Web of Science ®Google Scholar
• Wu Y, Lin B, Lu Y, et al. Aptamer-LYTACs for targeted degradation of extracellular and membrane proteins. Angew Chem Int Ed. 2023;62(15):e202218106. doi: 10.1002/anie.202218106
   PubMedGoogle Scholar
• Passariello M, Camorani S, Vetrei C, et al. Novel human bispecific aptamer-antibody conjugates for efficient cancer cell killing. Cancers (Basel). 2019;11(9):1268. doi: 10.3390/cancers11091268
   PubMed Web of Science ®Google Scholar
• Tang R, Fu YH, Gong B, et al. A chimeric conjugate of antibody and programmable DNA nanoassembly smartly activates T cells for precise cancer cell targeting. Angew Chem Int Ed. 2022;61(36):e202205902. doi: 10.1002/anie.202205902
   PubMed Web of Science ®Google Scholar
• Lambert JM. Antibody-drug conjugates (ADCs): magic bullets at last! Mol Pharm. 2015;12(6):1701–1702. doi: 10.1021/acs.molpharmaceut.5b00302
   PubMedGoogle Scholar
• Huang YF, Shangguan D, Liu H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem. 2009;10(5):862–868. doi: 10.1002/cbic.200800805
   PubMed Web of Science ®Google Scholar
• Carvalho C, Santos RX, Cardoso S, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16(25):3267–3285. doi: 10.2174/092986709788803312
   PubMed Web of Science ®Google Scholar
• Bagalkot V, Farokhzad OC, Langer R, et al. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed. 2006;45(48):8149–8152. doi: 10.1002/anie.200602251
   PubMed Web of Science ®Google Scholar
• Zeng Z, Qi J, Wan Q, et al. Aptamers with self-loading drug payload and pH-controlled drug release for targeted chemotherapy. Pharmaceutics. 2021;13(8):1221. doi: 10.3390/pharmaceutics13081221
   PubMed Web of Science ®Google Scholar
• Zhu G, Meng L, Ye M, et al. Self-assembled aptamer-based drug carriers for bispecific cytotoxicity to cancer cells. Chem Asian J. 2012;7(7):1630–1636. doi: 10.1002/asia.201101060
   PubMed Web of Science ®Google Scholar
• He J, Peng T, Peng Y, et al. Molecularly engineering triptolide with aptamers for high specificity and cytotoxicity for triple-negative breast cancer. J Am Chem Soc. 2020;142(6):2699–2703. doi: 10.1021/jacs.9b10510
   PubMed Web of Science ®Google Scholar
• Li Y, Peng Y, Tan Y, et al. A new paradigm for artesunate anticancer function: considerably enhancing the cytotoxicity via conjugating artesunate with aptamer. Signal Transduct Target Ther. 2021;6(1):327. doi: 10.1038/s41392-021-00671-8
   PubMed Web of Science ®Google Scholar
• Huang Z, Wang D, Long CY, et al. Regulating the anticancer efficacy of Sgc8-combretastatin A4 conjugates: a case of recognizing the significance of Linker chemistry for the design of aptamer-based targeted drug delivery strategies. J Am Chem Soc. 2021;143(23):8559–8564. doi: 10.1021/jacs.1c03013
   PubMed Web of Science ®Google Scholar
• Yang Q, Deng Z, Wang D, et al. Conjugating aptamer and mitomycin C with reductant-responsive linker leading to synergistically enhanced anticancer effect. J Am Chem Soc. 2020;142(5):2532–2540. doi: 10.1021/jacs.9b12409
   PubMed Web of Science ®Google Scholar
• Pan X, Yang Y, Li L, et al. A bispecific circular aptamer tethering a built-in universal molecular tag for functional protein delivery. Chem Sci. 2020;11(35):9648–9654. doi: 10.1039/D0SC02279A
   PubMed Web of Science ®Google Scholar
• Jiang Y, Pan X, Chang J, et al. Supramolecularly engineered circular bivalent aptamer for enhanced functional protein delivery. J Am Chem Soc. 2018;140(22):6780–6784. doi: 10.1021/jacs.8b03442
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang L, Cui C, et al. Enhanced targeted gene transduction: AAV2 vectors conjugated to multiple aptamers via reducible disulfide linkages. J Am Chem Soc. 2018;140(1):2–5. doi: 10.1021/jacs.7b08518
   PubMed Web of Science ®Google Scholar
• Esposito CL, Nuzzo S, Catuogno S, et al. STAT3 gene silencing by aptamer-siRNA chimera as selective therapeutic for glioblastoma. Mol Ther Nucleic Acids. 2018;10:398–411. doi: 10.1016/j.omtn.2017.12.021
   PubMedGoogle Scholar
• Shi X, Song P, Tao S, et al. Silencing RORγt in human CD4(+) T cells with CD30 aptamer-RORγt shRNA chimera. Sci Rep. 2019;9(1):10375. doi: 10.1038/s41598-019-46855-9
   PubMedGoogle Scholar
• Liu HY, Yu X, Liu H, et al. Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer. Sci Rep. 2016;6(1):30346. doi: 10.1038/srep30346
   PubMedGoogle Scholar
• Yu X, Ghamande S, Liu H, et al. Targeting EGFR/HER2/HER3 with a three-in-one aptamer-siRNA chimera confers superior activity against HER2(+) breast cancer. Mol Ther Nucleic Acids. 2018;10:317–330. doi: 10.1016/j.omtn.2017.12.015
   PubMedGoogle Scholar
• Yoo H, Jung H, Kim SA, et al. Multivalent comb-type aptamer-siRNA conjugates for efficient and selective intracellular delivery. Chem Commun (Camb). 2014;50(51):6765–6767. doi: 10.1039/c4cc01620c
   PubMed Web of Science ®Google Scholar
• Nuzzo S, Roscigno G, Affinito A, et al. Potential and challenges of aptamers as specific carriers of therapeutic oligonucleotides for precision medicine in cancer. Cancers (Basel). 2019;11(10):1521. doi: 10.3390/cancers11101521
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387–6392.
   PubMed Web of Science ®Google Scholar
• Xu X, Ho W, Zhang X, et al. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med. 2015;21(4):223–232. doi: 10.1016/j.molmed.2015.01.001
   PubMed Web of Science ®Google Scholar
• Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res. 1986;31(3):288–305. doi: 10.1016/0026-2862(86)90018-X
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Tavares A, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):1–12. doi: 10.1038/natrevmats.2016.14
   Web of Science ®Google Scholar
• Lee H, Shields AF, Siegel BA, et al. (64)Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer. Clin Cancer Res. 2017;23(15):4190–4202. doi: 10.1158/1078-0432.CCR-16-3193
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Korn RL, Raghunand N, et al. Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: a pilot study. Clin Cancer Res. 2017;23(14):3638–3648. doi: 10.1158/1078-0432.CCR-16-1990
   PubMed Web of Science ®Google Scholar
• Hu Q, Li H, Wang L, et al. DNA nanotechnology-enabled drug delivery systems. Chem Rev. 2019;119(10):6459–6506. doi: 10.1021/acs.chemrev.7b00663
   PubMed Web of Science ®Google Scholar
• Fan Q, He Z, Xiong J, et al. Smart drug delivery systems based on DNA nanotechnology. Chempluschem. 2022;87(3):e202100548. doi: 10.1002/cplu.202100548
   PubMed Web of Science ®Google Scholar
• Zhu G, Zheng J, Song E, et al. Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc Natl Acad Sci U S A. 2013;110(20):7998–8003. doi: 10.1073/pnas.1220817110
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang S, Yang Z, et al. An aptamer-nanotrain assembled from six-letter DNA delivers doxorubicin selectively to liver cancer cells. Angew Chem Int Ed. 2020;59(2):663–668. doi: 10.1002/anie.201909691
   PubMed Web of Science ®Google Scholar
• Zhang L, Abdullah R, Hu X, et al. Engineering of bioinspired, size-controllable, self-degradable cancer-targeting DNA nanoflowers via the incorporation of an artificial sandwich base. J Am Chem Soc. 2019;141(10):4282–4290. doi: 10.1021/jacs.8b10795
   PubMed Web of Science ®Google Scholar
• Xue C, Zhang S, Yu X, et al. Periodically ordered, nuclease-resistant DNA nanowires decorated with cell-specific aptamers as selective theranostic agents. Angew Chem Int Ed. 2020;59(40):17540–17547. doi: 10.1002/anie.202004805
   PubMed Web of Science ®Google Scholar
• Li J, Zheng C, Cansiz S, et al. Self-assembly of DNA nanohydrogels with controllable size and stimuli-responsive property for targeted gene regulation therapy. J Am Chem Soc. 2015;137(4):1412–1415. doi: 10.1021/ja512293f
   PubMed Web of Science ®Google Scholar
• Xuan W, Xia Y, Li T, et al. Molecular self-assembly of bioorthogonal aptamer-prodrug conjugate micelles for hydrogen peroxide and pH-independent cancer chemodynamic therapy. J Am Chem Soc. 2020;142(2):937–944. doi: 10.1021/jacs.9b10755
   PubMed Web of Science ®Google Scholar
• Li S, Jiang Q, Liu S, et al. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nat Biotechnol. 2018;36(3):258–264. doi: 10.1038/nbt.4071
   PubMed Web of Science ®Google Scholar
• Ouyang C, Zhang S, Xue C, et al. Precision-guided missile-like DNA nanostructure containing warhead and guidance control for aptamer-based targeted drug delivery into cancer cells in vitro and in vivo. J Am Chem Soc. 2020;142(3):1265–1277. doi: 10.1021/jacs.9b09782
   PubMed Web of Science ®Google Scholar
• Wang D, Li S, Zhao Z, et al. Engineering a second-order DNA logic-gated nanorobot to sense and release on live cell membranes for multiplexed diagnosis and synergistic therapy. Angew Chem Int Ed. 2021;60(29):15816–15820. doi: 10.1002/anie.202103993
   PubMed Web of Science ®Google Scholar
• Mahmoudpour M, Ding S, Lyu Z, et al. Aptamer functionalized nanomaterials for biomedical applications: recent advances and new horizons. Nano Today. 2021;39:101177. doi: 10.1016/j.nantod.2021.101177
   Web of Science ®Google Scholar
• Deng Z, Yang Q, Peng Y, et al. Polymeric engineering of aptamer-drug conjugates for targeted cancer therapy. Bioconjug Chem. 2020;31(1):37–42. doi: 10.1021/acs.bioconjchem.9b00715
   PubMed Web of Science ®Google Scholar
• Akuma P, Okagu O, Udenigwe CC. Naturally occurring exosome vesicles as potential delivery vehicle for bioactive compounds. Front Sustain Food Syst. 2019;3:23. doi: 10.3389/fsufs.2019.00023
   Google Scholar
• Liu Q, Bi C, Li J, et al. Generating giant membrane vesicles from live cells with preserved cellular properties. Research. 2019;2019:6523970. doi: 10.34133/2019/6523970
   PubMedGoogle Scholar
• Zou J, Shi M, Liu X, et al. Aptamer-functionalized exosomes: elucidating the cellular uptake mechanism and the potential for cancer-targeted chemotherapy. Anal Chem. 2019;91(3):2425–2430. doi: 10.1021/acs.analchem.8b05204
   PubMed Web of Science ®Google Scholar
• Luo C, Hu X, Peng R, et al. Biomimetic carriers based on giant membrane vesicles for targeted drug delivery and photodynamic/photothermal synergistic therapy. ACS Appl Mater Interfaces. 2019;11(47):43811–43819. doi: 10.1021/acsami.9b11223
   PubMed Web of Science ®Google Scholar
• Esfahani K, Roudaia L, Buhlaiga NA, et al. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27(s2):87–97. doi: 10.3747/co.27.5223
   Google Scholar
• van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39–50. doi: 10.1038/s41591-021-01643-9
   PubMed Web of Science ®Google Scholar
• Weber EW, Maus M, Mackall CL. The emerging landscape of immune cell therapies. Cell. 2020;181(1):46–62. doi: 10.1016/j.cell.2020.03.001
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restif N, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299–308. doi: 10.1038/nrc2355
   PubMed Web of Science ®Google Scholar
• R K. Cancer immunoediting: from immune surveillance to immune escape. Cancer Immunother. 2007;9:27.
   Google Scholar
• Xiong X, Liu H, Zhao Z, et al. DNA aptamer‐mediated cell targeting. Angew Chem Int Ed. 2013;152(5):1512–1516. doi: 10.1002/ange.201207063
   Google Scholar
• Shi P, Wang X, Davis B, et al. In situ synthesis of an aptamer-based polyvalent antibody mimic on the cell surface for enhanced interactions between immune and cancer cells. Angew Chem Int Ed. 2020;59(29):11892–11897. doi: 10.1002/anie.202004206
   PubMed Web of Science ®Google Scholar
• Zhang D, Zheng Y, Lin Z, et al. Equipping natural killer cells with specific targeting and checkpoint blocking aptamers for enhanced adoptive immunotherapy in solid tumors. Angew Chem Int Ed. 2020;59(29):12022–12028. doi: 10.1002/anie.202002145
   PubMed Web of Science ®Google Scholar
• Belgiovine C, Digifico E, Anfray C, et al. Targeting tumor-associated macrophages in anti-cancer therapies: convincing the traitors to do the right thing. J Clin Med. 2020;9(10):3226. doi: 10.3390/jcm9103226
   PubMed Web of Science ®Google Scholar
• Xia Y, Rao L, Yao H, et al. Engineering macrophages for cancer immunotherapy and drug delivery. Adv Mater. 2020;32(40):e2002054. doi: 10.1002/adma.202002054
   PubMed Web of Science ®Google Scholar
• Qian H, Fu Y, Guo M, et al. Dual-aptamer-engineered M1 macrophage with enhanced specific targeting and checkpoint blocking for solid-tumor immunotherapy. Mol Ther. 2022;30(8):2817–2827. doi: 10.1016/j.ymthe.2022.04.015
   PubMed Web of Science ®Google Scholar
• Maru B, Nadeau L, McKeague M. Enhancing CAR-T cell therapy with functional nucleic acids. ACS Pharmacol Transl Sci. 2021;4(6):1716–1727. doi: 10.1021/acsptsci.1c00188
   PubMedGoogle Scholar
• Liu CG, Wang Y, Liu P, et al. Aptamer-T cell targeted therapy for tumor treatment using sugar metabolism and click chemistry. ACS Chem Biol. 2020;15(6):1554–1565. doi: 10.1021/acschembio.0c00164
   PubMed Web of Science ®Google Scholar
• Wang T, Chen C, Larcher LM, et al. Three decades of nucleic acid aptamer technologies: lessons learned, progress and opportunities on aptamer development. Biotechnol Adv. 2019;37(1):28–50. doi: 10.1016/j.biotechadv.2018.11.001
   PubMed Web of Science ®Google Scholar
• Zhao L, Qi X, Yan X, et al. Engineering aptamer with enhanced affinity by triple helix-based terminal fixation. J Am Chem Soc. 2019;141(44):17493–17497. doi: 10.1021/jacs.9b09292
   PubMed Web of Science ®Google Scholar
• Yoshikawa AM, Rangel A, Feagin T, et al. Discovery of indole-modified aptamers for highly specific recognition of protein glycoforms. Nat Commun. 2021;12(1):7106. doi: 10.1038/s41467-021-26933-1
   PubMed Web of Science ®Google Scholar
• Yue H, Chen J, Chen X, et al. Systematic screening and optimization of single-stranded DNA aptamer specific for N-acetylneuraminic acid: A comparative study. Sens Actuators B Chem. 2021;344:130270. doi: 10.1016/j.snb.2021.130270
   Web of Science ®Google Scholar